Insider · CIK 0001914503

Easom Eric

CIK 0001914503 Name as filed on the most recent filing

Filed as Easom Eric (11)

26 transaction lines · from 11 filings · filed 2022-10-24 to 2025-06-03 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

26 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-06-02 P, Open-market purchase An2 Therapeutics, Inc.ANTX 10,665, acquired Open Form 4 filing 0000950170-25-081041
2024-11-18 P, Open-market purchase An2 Therapeutics, Inc.ANTX 49,970, acquired Open Form 4 filing 0000950170-24-128202
2024-01-02 S, Open-market sale An2 Therapeutics, Inc.ANTX 55,802, disposed Open Form 4 filing 0001610717-24-000013
2023-05-15 P, Open-market purchase An2 Therapeutics, Inc.ANTX 53,770, acquired Open Form 4 filing 0000899243-23-013012
2022-11-14 S, Open-market sale An2 Therapeutics, Inc.ANTX 346, disposed Open Form 4 filing 0000899243-22-035782
2022-11-10 S, Open-market sale An2 Therapeutics, Inc.ANTX 67,628, disposed Open Form 4 filing 0000899243-22-035782
2022-11-09 S, Open-market sale An2 Therapeutics, Inc.ANTX 157,847, disposed Open Form 4 filing 0000899243-22-035472
2022-11-08 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 109,947, disposed Open Form 4 filing 0000899243-22-035472
2022-11-07 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 195,741, disposed Open Form 4 filing 0000899243-22-035311
2022-11-04 S, Open-market sale An2 Therapeutics, Inc.ANTX 139,474, disposed Open Form 4 filing 0000899243-22-035311
2022-11-03 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 223,058, disposed Open Form 4 filing 0000899243-22-035311
2022-11-02 S, Open-market sale An2 Therapeutics, Inc.ANTX 23,263, disposed Open Form 4 filing 0000899243-22-034840
2022-10-31 S, Open-market sale An2 Therapeutics, Inc.ANTX 41,363, disposed Open Form 4 filing 0000899243-22-034840
2022-10-28 S, Open-market sale An2 Therapeutics, Inc.ANTX 25,392, disposed Open Form 4 filing 0000899243-22-034497
2022-10-27 S, Open-market sale An2 Therapeutics, Inc.ANTX 14,190, disposed Open Form 4 filing 0000899243-22-034497
2022-10-26 S, Open-market sale An2 Therapeutics, Inc.ANTX 25,342, disposed Open Form 4 filing 0000899243-22-034294
2022-10-25 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 75,672, disposed Open Form 4 filing 0000899243-22-034294
2022-10-24 S, Open-market sale An2 Therapeutics, Inc.ANTX 46,344, disposed Open Form 4 filing 0000899243-22-034294
2022-10-21 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 228,240, disposed Open Form 4 filing 0000899243-22-034092
2022-10-20 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 121,672, disposed Open Form 4 filing 0000899243-22-034092

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 3
  • Open-market sale 23
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Easom Eric, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001914503

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.